EicOsis Initiates Phase 1b Clinical Trial of EC5026

EC5026 is the first soluble epoxide hydrolase inhibitor (sEHI) developed to treat pain DAVIS, Calif., Jan. 30, 2024 /PRNewswire/ — EicOsis Human Health, a pharmaceutical company engaged in the development of a novel category of non-narcotic oral analgesics centered around the inhibition…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Advertisement — Advertise with Biotech Networks